全文获取类型
收费全文 | 1243篇 |
免费 | 67篇 |
国内免费 | 22篇 |
学科分类
医药卫生 | 1332篇 |
出版年
2021年 | 13篇 |
2020年 | 11篇 |
2019年 | 15篇 |
2018年 | 21篇 |
2017年 | 11篇 |
2016年 | 14篇 |
2015年 | 21篇 |
2014年 | 26篇 |
2013年 | 39篇 |
2012年 | 41篇 |
2011年 | 40篇 |
2010年 | 32篇 |
2009年 | 35篇 |
2008年 | 38篇 |
2007年 | 51篇 |
2006年 | 36篇 |
2005年 | 46篇 |
2004年 | 39篇 |
2003年 | 35篇 |
2002年 | 41篇 |
2001年 | 58篇 |
2000年 | 35篇 |
1999年 | 23篇 |
1998年 | 36篇 |
1997年 | 51篇 |
1996年 | 31篇 |
1995年 | 34篇 |
1994年 | 21篇 |
1993年 | 15篇 |
1992年 | 18篇 |
1991年 | 19篇 |
1990年 | 21篇 |
1989年 | 32篇 |
1988年 | 37篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 28篇 |
1984年 | 20篇 |
1983年 | 13篇 |
1982年 | 21篇 |
1981年 | 15篇 |
1980年 | 20篇 |
1979年 | 16篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1976年 | 21篇 |
1975年 | 12篇 |
1974年 | 8篇 |
1970年 | 10篇 |
1969年 | 7篇 |
排序方式: 共有1332条查询结果,搜索用时 15 毫秒
1.
2.
Tiffany C. Ho Boris Gutman Elena Pozzi Hans J. Grabe Norbert Hosten Katharina Wittfeld Henry Vlzke Bernhard Baune Udo Dannlowski Katharina Frster Dominik Grotegerd Ronny Redlich Andreas Jansen Tilo Kircher Axel Krug Susanne Meinert Igor Nenadic Nils Opel Richard Dinga Dick J. Veltman Knut Schnell Ilya Veer Henrik Walter Ian H. Gotlib Matthew D. Sacchet Andr Aleman Nynke A. Groenewold Dan J. Stein Meng Li Martin Walter Christopher R. K. Ching Neda Jahanshad Anjanibhargavi Ragothaman Dmitry Isaev Artemis Zavaliangos-Petropulu Paul M. Thompson Philipp G. Smann Lianne Schmaal 《Human brain mapping》2022,43(1):341-351
Alterations in regional subcortical brain volumes have been investigated as part of the efforts of an international consortium, ENIGMA, to identify reliable neural correlates of major depressive disorder (MDD). Given that subcortical structures are comprised of distinct subfields, we sought to build significantly from prior work by precisely mapping localized MDD-related differences in subcortical regions using shape analysis. In this meta-analysis of subcortical shape from the ENIGMA-MDD working group, we compared 1,781 patients with MDD and 2,953 healthy controls (CTL) on individual measures of shape metrics (thickness and surface area) on the surface of seven bilateral subcortical structures: nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus. Harmonized data processing and statistical analyses were conducted locally at each site, and findings were aggregated by meta-analysis. Relative to CTL, patients with adolescent-onset MDD (≤ 21 years) had lower thickness and surface area of the subiculum, cornu ammonis (CA) 1 of the hippocampus and basolateral amygdala (Cohen's d = ?0.164 to ?0.180). Relative to first-episode MDD, recurrent MDD patients had lower thickness and surface area in the CA1 of the hippocampus and the basolateral amygdala (Cohen's d = ?0.173 to ?0.184). Our results suggest that previously reported MDD-associated volumetric differences may be localized to specific subfields of these structures that have been shown to be sensitive to the effects of stress, with important implications for mapping treatments to patients based on specific neural targets and key clinical features. 相似文献
3.
4.
5.
Richard S. Finn Hope S. Rugo Karen A. Gelmon Massimo Cristofanilli Marco Colleoni Sherene Loi Patrick Schnell Dongrui R. Lu Kathy Puyana Theall Ave Mori Eric Gauthier Eustratios Bananis Nicholas C. Turner Véronique Diéras 《The oncologist》2021,26(5):e749-e755
BackgroundPrevious studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure.Patients and MethodsData were pooled from three randomized studies of patients with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) advanced breast cancer (ABC), including postmenopausal women who had not received prior systemic treatment for advanced disease (PALOMA‐1/‐2) and pre‐ and postmenopausal women who had progressed on prior ET (PALOMA‐3).ResultsUpdated cutoff dates were December 21, 2017 (PALOMA‐1), May 31, 2017 (PALOMA‐2), and April 13, 2018 (PALOMA‐3). Total person‐years of treatment exposure were 1,421.6 with palbociclib plus ET (n = 872) and 528.4 with ET (n = 471). Any‐grade neutropenia and infections were more frequent with palbociclib plus ET (82.1% and 59.2%, respectively) than with ET (5.1% and 39.5%). The hazard ratios were 1.6 (p = .0995) for grade 3/4 infections, 1.8 (p = .4358) for grade 3/4 viral infections, 1.4 (p = .0001) for infections, and 30.8 (p < .0001) for neutropenia. Febrile neutropenia was reported in 1.4% of patients receiving palbociclib plus ET. Cumulative incidence of all‐grade hematologic adverse events in both arms peaked during the first year of treatment and plateaued over the 5 subsequent years. Interstitial lung disease was reported in 13 patients receiving palbociclib plus ET and 3 receiving ET.ConclusionThis 5‐year, long‐term analysis demonstrated that palbociclib plus ET has a consistent and stable safety profile and is a safe treatment for patients with HR+/HER2− ABC.Implications for PracticeSeveral treatments for patients with breast cancer are associated with long‐term or latent adverse events. This long‐term, 5‐year analysis demonstrated that palbociclib plus endocrine therapy has a consistent and stable safety profile without cumulative or delayed toxicities. These results further support palbociclib plus endocrine therapy as a safe and manageable treatment in clinical practice for patients with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. 相似文献
6.
Gretja Schnell Rakesh Tripathi Jill Beyer Thomas Reisch Preethi Krishnan Liangjun Lu Tatyana Dekhtyar Coleen Hall Regis A. Vilchez Tami Pilot-Matias Christine Collins 《Antimicrobial agents and chemotherapy》2015,59(11):6807-6815
Hepatitis C virus (HCV) genotype 4 (GT4) is genetically diverse, with 17 confirmed subtypes, and comprises approximately 13% of infections worldwide. In this study, we identified GT4 subtypes by phylogenetic analysis, assessed differences in patient demographics across GT4 subtypes, examined baseline sequence variability among subtypes and the potential impact on treatment outcome, and analyzed the development of viral resistance in patients who received a regimen of ombitasvir (nonstructural protein 5A [NS5A] inhibitor) plus ritonavir-boosted paritaprevir (NS3/4A inhibitor) with or without ribavirin (RBV) for the treatment of HCV GT4 infection. Phylogenetic analysis of HCV NS3/4A, NS5A, and NS5B nucleotide sequences identified 7 subtypes (4a, 4b, 4c, 4d, 4f, 4g/4k, and 4o) among 132 patient samples. Subtype prevalence varied by country, and the distributions of patient birth cohort and race were significantly different across GT4 subtypes 4a, 4d, and non-4a/4d. Baseline amino acid variability was detected in NS5A across GT4 subtypes but had no impact on treatment outcome. Three patients experienced virologic failure and were infected with subtype 4d, and the predominant resistance-associated variants at the time of failure were D168V in NS3 and L28V in NS5A. Overall, high response rates were observed among patients infected with 7 HCV GT4 subtypes, with no impact of baseline variants on treatment outcome. GT4 subtype distribution in this study differed based on patient demographics and geography. 相似文献
7.
8.
Agostino Consoli MD Leszek Czupryniak MD Rui Duarte MD György Jermendy MD Alexandra Kautzky-Willer MD Chantal Mathieu MD Miguel Melo MD Ofri Mosenzon MD Frank Nobels MD Nikolaos Papanas MD Gabriela Roman MD Oliver Schnell MD Alexis Sotiropoulos MD Coen D. A. Stehouwer MD Cees J. Tack MD Vincent Woo MD Gian Paolo Fadini MD Itamar Raz MD 《Diabetes, obesity & metabolism》2020,22(10):1705-1713
The large number of pharmacological agents available to treat type 2 diabetes (T2D) makes choosing the optimal drug for any given patient a complex task. Because newer agents offer several advantages, whether and when sulphonylureas (SUs) should still be used to treat T2D is controversial. Published treatment guidelines and recommendations should govern the general approach to diabetes management. However, expert opinions can aid in better understanding local practices and in formulating individual choices. The current consensus paper aims to provide additional guidance on the use of SUs in T2D. We summarize current local treatment guidelines in European countries, showing that SUs are still widely proposed as second-line treatment after metformin and are often ranked at the same level as newer glucose-lowering medications. Strong evidence now shows that sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with low hypoglycaemia risk, promote weight loss, and exert a positive impact on vascular, cardiac and renal endpoints. Thus, using SUs in place of SGLT-2is and GLP-1RAs may deprive patients of key advantages and potentially important cardiorenal benefits. In subjects with ascertained cardiovascular disease or at very high cardiovascular risk, SGLT-2is and/or GLP-1RAs should be used as part of diabetes management, in the absence of contraindications. Routine utilization of SUs as second-line agents continues to be acceptable in resource-constrained settings. 相似文献
9.
10.
Hannah Lilly Mackenzie Bitzel Tatiana Pejnovic Joanna Schnell 《Physical Therapy Reviews》2019,24(5):195-207
AbstractBackground: Cerebral palsy (CP) is a common childhood disability. However, these individuals are now living longer lives, participating in adult roles, and seeking healthcare services. The transition from pediatric to adult healthcare for adolescents with CP is a challenging yet significant time. Adolescents experience several barriers during transition.Objectives: To utilize the environmental and personal dimensions of the ICF model in order to explore barriers when transitioning to adulthood as well as discuss characteristics and physical therapy implications needed to succeed within transition.Methods: Electronic searching of PubMed, CINAHL, ERIC, Scopus, ProQuest, and the Cochrane Library databases was concluded on January 9, 2019 for studies including transition between pediatric and adult healthcare in individuals diagnosed with CP. Two independent reviewers agreed upon inclusion, eligibility, and quality assessment of each study using the Mixed-Methods Appraisal Tool (MMAT).Results: Seven studies were included in the systematic review. Results for each study were separated based on the personal and environmental contextual factors of the ICF model and solutions to the barriers were then discussed.Conclusions: Research has provided proposed solutions to select barriers, however, other barriers have yet to be addressed. More research is needed to address these barriers and provide a model program that can be implemented within the healthcare systems to promote a successful transition for adolescents with CP from pediatric to adult services. 相似文献